2023 World Conference on Lung Cancer (Posters)-EP07.05. CDDP/TS1 Followed by Maintenance TS1 as Adjuvant Chemotherapy in Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer

EP07.05. CDDP/TS1 Followed by Maintenance TS1 as Adjuvant Chemotherapy in Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

This phase II trial evaluated the feasibility and efficacy of adjuvant chemotherapy with a combination of CDDP and TS1 followed by maintenance TS1 therapy in patients with completely resected stage II-IIIA non-small cell lung cancer (NSCLC). The study aimed to assess the treatment completion rate, adverse events, and survival outcomes.<br /><br />A total of 59 patients were enrolled in the study from multiple institutions between August 2013 and October 2018. The primary endpoint was the treatment completion rate, which was found to be 57.6% according to the planned protocol. The secondary endpoints included adverse events, 3-year recurrence-free survival (RFS), and overall survival (OS) rates.<br /><br />The 3-year RFS was reported to be 62.5%, indicating a favorable outcome in terms of preventing tumor recurrence. The 2-year OS was 88.1% and the 3-year OS was 82.9%, suggesting good overall survival rates.<br /><br />Notably, the CDDP/TS1 combination therapy followed by TS1 every other day maintenance regimen showed a high completion rate compared to the conventional method of taking TS1 orally for 14 days followed by a 7-day rest. There were no treatment-related deaths or grade 4 or higher adverse events observed during the study.<br /><br />These findings suggest that adjuvant chemotherapy with CDDP/TS1 followed by maintenance TS1 therapy may be feasible and improve treatment completion rates in completely resected stage II-IIIA NSCLC. This approach has the potential to enhance patient outcomes in terms of recurrence-free survival and overall survival.<br /><br />However, it is important to note that this study was conducted as a phase II trial, and further research is needed to validate these findings in larger clinical trials. Nonetheless, this study provides promising results for the use of CDDP/TS1 combination therapy followed by maintenance TS1 therapy as adjuvant chemotherapy in surgically resected NSCLC.

Asset Subtitle

Kosuke Fujino

Meta Tag

Speaker Kosuke Fujino

Topic Early-Stage NSCLC: Pushing the Boundaries

Keywords

adjuvant chemotherapy

CDDP

TS1

feasibility

efficacy

non-small cell lung cancer

treatment completion rate

adverse events

recurrence-free survival

overall survival